Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

TARGET Study Finds Major Differences between Childhood and Adult AML

(NCI/Cancer Currents Blog) Jan 30, 2018 - An NCI-funded study has found that, at the genetic level, acute myeloid leukemia (AML) differs greatly between younger and older patients.

read article

Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

(Novartis) Jan 31, 2018 - Novartis today announced updated results from the pivotal ELIANA clinical trial of KymriahTM (tisagenlecleucel), formerly CTL019, in relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) have been published in The New England Journal of Medicine (NEJM).

read corporate press release

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

(Morningstar) Feb 1, 2018 - Boston-based cancer company Partner Therapeutics, Inc. announced today that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

read article

New CAR T Cell for Adult ALL, 'Game Changer' in Pediatric ALL

(Medscape Medical News) Feb 1, 2018 - A new CAR T cell has shown efficacy in adults with acute lymphoblastic leukemia (ALL), as the first of these products is hailed as a 'game changer' in pediatric ALL.

read article (free registration required)

Unique Research Approach Finds FDA Approved Drug Shuts Down Ewing Sarcoma Cells In Lab

(GUMC) Jan 30, 2018 - Based on a novel approach to drug discovery, researchers at Georgetown Lombardi Comprehensive Cancer Center say an agent approved to treat a type of leukemia might also help young people with a much rarer and aggressive form of cancer, Ewing sarcoma.

read press release

CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report

(ASCO) Jan 30, 2018 - Released today in advance of World Cancer Day, Clinical Cancer Advances 2018 highlights the most impactful clinical cancer research and policy developments over the past year.

read press release

Intravenous Combination Regimen Safe, Effective in Older Patients With Type of Blood Malignancy

(Journal of Clinical Pathways) Jan 23, 2018 - A potential new first-line therapeutic option may have been identified for older patients with a common blood cancer type.

read article

MSK Opens New Clinic to Monitor People with a Genetic Risk for Developing Blood Cancer

(MSK/On Cancer blog) Jan 23, 2018 - MSK’s new clinic will focus on clonal hematopoiesis, a condition related to aging that increases the risk of developing certain blood cancers.

read article

Sanofi Beats Novo To Buy Ablynx For $4.8 Billion In Biotech M&A Boom

(Reuters) Jan 29, 2018 - French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.

read article

Old Drug May Have New Tricks For Fighting Cancer

(Arizona State University) Feb 4, 2018 - In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases.

read press release

UF Health Pediatric Oncology Patients Pilot HealthSteps Mobile Platform

(UF Health) Feb 6, 2018 - A select group of University of Florida Health pediatric oncology patients are being enrolled in a trial for HealthSteps — a smartphone-based digital care plan with clear patient care instructions, built-in reminders, a symptom tracker and the ability to share care plans between family members and medical teams.

read article

Web-Based Intervention Helps Kids Stay Physically Active After Cancer Treatment

(2018 Cancer Survivorship Symposium) Feb 12, 2018 - A pilot study of cancer survivors ages 11-15 suggests that a web-based, interactive intervention that provides rewards for exercising can motivate kids to stay physically active.

read press release

Nohla Therapeutics Initiates Global Launch Phase 2 Trial Of NLA101 In Patients With AML

(Nohla) Feb 13, 2018 - Nohla Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of universal, off-the-shelf cell therapies to treat cancer and other critical diseases, today announced the initiation of its Phase 2 LAUNCH clinical trial.

read corporate press release

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

(MarketWatch) Feb 14, 2018 - The sBLA for BLINCYTO was accepted by the FDA for priority review, and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2018 has been set.

read article

National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos (TM) (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology

(StreetInsider) Feb 8, 2018 - Jazz Pharmaceuticals plc today announced that the National Comprehensive Cancer Network® (NCCN®) added Vyxeos™ (daunorubicin and cytarabine) liposome for injection to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia (AML).

read article

Breakthrough Cancer Therapy Raises Tough Questions About Drug Costs, Value

(Philadelphia Inquirer) Feb 6, 2018 - Imagine a drug that, a month after a single intravenous dose, wipes out all evidence of leukemia in 80 percent of deathly ill children who receive it.

read article

Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients

(Yahoo! Finance) Feb 6, 2018 - Actinium Pharmaceuticals, Inc., announced today that the Company is initiating a new clinical trial that will study Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).

read article

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

(Xconomy Boston) Feb 7, 2018 - Verastem has filed for FDA approval of duvelisib, a blood cancer drug the Boston company took a shot on in a 2016 bargain deal with Infinity Pharmaceuticals.

read article

Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

(Forbes) Feb 8, 2018 - David Mitchell, 67, says he’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.

read article

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

(Agios) Feb 15, 2018 - Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.

read corporate press release
Next Page